Akums Drugs Releases Quarterly Financial Results for Q1 2026; Standalone Profit Stands at 448.39 Million
Akums Drugs and Pharmaceuticals Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's operational performance was reviewed by Statutory Auditors Walker Chandiok & Co LLP.The Board of Directors considered and approved the results, which are presented in alignment with Indian Accounting Standard 34 (Ind AS 34).
Financial Performance Snapshot (Standalone)
For the quarter ended June 30, 2026, Akums reported a total income of 4,183.79 million, down from 3,609.98 million in the corresponding period of the previous year. The company reported a profit for the quarter at 448.39 million.Key financial metrics for the standalone results are summarized below:
| Metric | Q ended 30 June 2026 (Unaudited) | Q ended 31 March 2026 (Unaudited) | Q ended 30 June 2025 (Unaudited) | Year ended 31 March 2026 (Audited) |
|---|---|---|---|---|
| Total Income | 4,183.79 million | 3,661.01 million | 3,609.98 million | 14,617.01 million |
| Total Expenses | 3,590.43 million | 3,415.99 million | 3,014.92 million | 13,068.17 million |
| Profit Before Tax | 593.36 million | 245.02 million | 595.06 million | 1,548.84 million |
| Profit for the Quarter/Year (Net) | 448.39 million | 151.97 million | 448.67 million | 1,116.40 million |
Group Performance and Segment Results
The consolidated results reflected revenue from operations at 11,666.2 prime million for the quarter ended June 30, 2026, compared to 10,240.32 million in the same period of the previous year. The consolidated entity reported a profit for the quarter of 2,563.97 million.The company's operations span multiple segments, including Domestic branded formulations and International branded formulations. The results provide a detailed look into segment performance and allocated corporate assets and liabilities.
Tax Demand and Corporate Matters
The audit review noted that tax demand amounting to 600.92 million had been raised by the Income-tax authorities for the block period spanning April 2018 to March 2025, relating to a search and seizure operation. The company has filed an appeal under section 246A of the Income-Tax Act before the Commissioner of Income-tax (Appeals), with management stating that no adjustments are required in the results regarding this demand.For the consolidated entity, a tax demand of 1,560.18 million was raised by the authorities for the same block period. The Group has also filed an appeal against this assessment order.
IPO Proceeds and Fund Utilization Status
The company reported that it received proceeds of 6,421.80 million through its Initial Public Offer (IPO) in August 2024. During the quarter ended June 30, 2026, the company confirmed full utilization of the net IPO proceeds towards designated objects of the issue.The utilization breakdown shows that the entire amount was deployed across various objectives:
| Object | Revised Net Proceeds (Million) | Actual Utilization Upto June 2026 (Million) |
|---|---|---|
| Repayment/prepayment of borrowings of Holding Company | 1,599.10 | 1,599.10 |
| Repayment/prepayment of subsidiaries' borrowings | 2,270.90 | 2,270.90 |
| Funding incremental working capital requirements | 550.00 | 550.00 |
| Pursuing inorganic growth initiatives | 301.80 | 301.80 |
| General corporate purposes (GCP) | 1,700.00 | 1,700.00 |
| Total Proceeds | 6,421.80 | 6,421.80 |
Other Corporate Updates
The company's operations continue in the pharmaceutical segment. The Board of Directors had previously allocated an excess provision of 48.10 million, which was subsequently reallocated to corporate purposes and inorganic growth initiatives pursuant to a resolution dated February 13, 2026.AKUMS Stock Price Movement
Akums Drugs and Pharmaceuticals Limited shares edged higher on Friday, closing at ₹697.45 after the stock gained 4.90%. The company's equity settled amidst strong trading activity, with 637,075 shares changing hands during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: